カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

腺筋症治療薬の世界市場2022：ホルモン剤、抗炎症剤、その他

◆英語タイトル：Global Adenomyosis Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22NO19101）◆商品コード：GIR22NO19101
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2022年11月（※2025年版があります。お問い合わせください。）
◆ページ数：110
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

腺筋症治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の腺筋症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

腺筋症治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ホルモン剤、抗炎症剤、その他

用途別セグメントは次のように区分されます。
・病院、診療所、薬局、その他

世界の腺筋症治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Accord Healthcare、Tolmar Pharmaceuticals、Mayne Pharma Group、Hikma Pharmaceuticals PLC、Boehringer Ingelheim International GmbH、TerSera Therapeutics、Ferring Pharmaceuticals、Lannett、Endo International、Context Therapeutics、Viatris、Bayer AG、Teva Pharmaceutical Industries、AstraZeneca、Sanofi、Merck、Novartis、Pfizer

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、腺筋症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な腺筋症治療薬メーカーの企業概要、2019年～2022年までの腺筋症治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な腺筋症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別腺筋症治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの腺筋症治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での腺筋症治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および腺筋症治療薬の産業チェーンを掲載しています。
・第13、14、15章では、腺筋症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 腺筋症治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：ホルモン剤、抗炎症剤、その他
- 用途別分析（2017年vs2021年vs2028年）：病院、診療所、薬局、その他
- 世界の腺筋症治療薬市場規模・予測
- 世界の腺筋症治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Accord Healthcare、Tolmar Pharmaceuticals、Mayne Pharma Group、Hikma Pharmaceuticals PLC、Boehringer Ingelheim International GmbH、TerSera Therapeutics、Ferring Pharmaceuticals、Lannett、Endo International、Context Therapeutics、Viatris、Bayer AG、Teva Pharmaceutical Industries、AstraZeneca、Sanofi、Merck、Novartis、Pfizer
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ホルモン剤、抗炎症剤、その他
・用途別分析2017年-2028年：病院、診療所、薬局、その他
・腺筋症治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・腺筋症治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・腺筋症治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・腺筋症治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・腺筋症治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Adenomyosis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Adenomyosis Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospitals accounting for % of the Adenomyosis Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Hormone Medications segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Adenomyosis Drugs include Accord Healthcare, Tolmar Pharmaceuticals, Mayne Pharma Group, Hikma Pharmaceuticals PLC, and Boehringer Ingelheim International GmbH, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Adenomyosis Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Hormone Medications
Anti-inflammatory Drugs
Others
Market segment by Application can be divided into
Hospitals
Clinics
Pharmacy
Others
The key market players for global Adenomyosis Drugs market are listed below:
Accord Healthcare
Tolmar Pharmaceuticals
Mayne Pharma Group
Hikma Pharmaceuticals PLC
Boehringer Ingelheim International GmbH
TerSera Therapeutics
Ferring Pharmaceuticals
Lannett
Endo International
Context Therapeutics
Viatris
Bayer AG
Teva Pharmaceutical Industries
AstraZeneca
Sanofi
Merck
Novartis
Pfizer
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adenomyosis Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Adenomyosis Drugs, with price, sales, revenue and global market share of Adenomyosis Drugs from 2019 to 2022.
Chapter 3, the Adenomyosis Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adenomyosis Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Adenomyosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Adenomyosis Drugs.
Chapter 13, 14, and 15, to describe Adenomyosis Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Adenomyosis Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Adenomyosis Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Hormone Medications
1.2.3 Anti-inflammatory Drugs
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Adenomyosis Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Pharmacy
1.3.5 Others
1.4 Global Adenomyosis Drugs Market Size & Forecast
1.4.1 Global Adenomyosis Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Adenomyosis Drugs Sales in Volume (2017-2028)
1.4.3 Global Adenomyosis Drugs Price (2017-2028)
1.5 Global Adenomyosis Drugs Production Capacity Analysis
1.5.1 Global Adenomyosis Drugs Total Production Capacity (2017-2028)
1.5.2 Global Adenomyosis Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Adenomyosis Drugs Market Drivers
1.6.2 Adenomyosis Drugs Market Restraints
1.6.3 Adenomyosis Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Accord Healthcare
2.1.1 Accord Healthcare Details
2.1.2 Accord Healthcare Major Business
2.1.3 Accord Healthcare Adenomyosis Drugs Product and Services
2.1.4 Accord Healthcare Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Tolmar Pharmaceuticals
2.2.1 Tolmar Pharmaceuticals Details
2.2.2 Tolmar Pharmaceuticals Major Business
2.2.3 Tolmar Pharmaceuticals Adenomyosis Drugs Product and Services
2.2.4 Tolmar Pharmaceuticals Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Mayne Pharma Group
2.3.1 Mayne Pharma Group Details
2.3.2 Mayne Pharma Group Major Business
2.3.3 Mayne Pharma Group Adenomyosis Drugs Product and Services
2.3.4 Mayne Pharma Group Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Hikma Pharmaceuticals PLC
2.4.1 Hikma Pharmaceuticals PLC Details
2.4.2 Hikma Pharmaceuticals PLC Major Business
2.4.3 Hikma Pharmaceuticals PLC Adenomyosis Drugs Product and Services
2.4.4 Hikma Pharmaceuticals PLC Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Boehringer Ingelheim International GmbH
2.5.1 Boehringer Ingelheim International GmbH Details
2.5.2 Boehringer Ingelheim International GmbH Major Business
2.5.3 Boehringer Ingelheim International GmbH Adenomyosis Drugs Product and Services
2.5.4 Boehringer Ingelheim International GmbH Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 TerSera Therapeutics
2.6.1 TerSera Therapeutics Details
2.6.2 TerSera Therapeutics Major Business
2.6.3 TerSera Therapeutics Adenomyosis Drugs Product and Services
2.6.4 TerSera Therapeutics Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Ferring Pharmaceuticals
2.7.1 Ferring Pharmaceuticals Details
2.7.2 Ferring Pharmaceuticals Major Business
2.7.3 Ferring Pharmaceuticals Adenomyosis Drugs Product and Services
2.7.4 Ferring Pharmaceuticals Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Lannett
2.8.1 Lannett Details
2.8.2 Lannett Major Business
2.8.3 Lannett Adenomyosis Drugs Product and Services
2.8.4 Lannett Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Endo International
2.9.1 Endo International Details
2.9.2 Endo International Major Business
2.9.3 Endo International Adenomyosis Drugs Product and Services
2.9.4 Endo International Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Context Therapeutics
2.10.1 Context Therapeutics Details
2.10.2 Context Therapeutics Major Business
2.10.3 Context Therapeutics Adenomyosis Drugs Product and Services
2.10.4 Context Therapeutics Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Viatris
2.11.1 Viatris Details
2.11.2 Viatris Major Business
2.11.3 Viatris Adenomyosis Drugs Product and Services
2.11.4 Viatris Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Bayer AG
2.12.1 Bayer AG Details
2.12.2 Bayer AG Major Business
2.12.3 Bayer AG Adenomyosis Drugs Product and Services
2.12.4 Bayer AG Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Teva Pharmaceutical Industries
2.13.1 Teva Pharmaceutical Industries Details
2.13.2 Teva Pharmaceutical Industries Major Business
2.13.3 Teva Pharmaceutical Industries Adenomyosis Drugs Product and Services
2.13.4 Teva Pharmaceutical Industries Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 AstraZeneca
2.14.1 AstraZeneca Details
2.14.2 AstraZeneca Major Business
2.14.3 AstraZeneca Adenomyosis Drugs Product and Services
2.14.4 AstraZeneca Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Sanofi
2.15.1 Sanofi Details
2.15.2 Sanofi Major Business
2.15.3 Sanofi Adenomyosis Drugs Product and Services
2.15.4 Sanofi Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Merck
2.16.1 Merck Details
2.16.2 Merck Major Business
2.16.3 Merck Adenomyosis Drugs Product and Services
2.16.4 Merck Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 Novartis
2.17.1 Novartis Details
2.17.2 Novartis Major Business
2.17.3 Novartis Adenomyosis Drugs Product and Services
2.17.4 Novartis Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Pfizer
2.18.1 Pfizer Details
2.18.2 Pfizer Major Business
2.18.3 Pfizer Adenomyosis Drugs Product and Services
2.18.4 Pfizer Adenomyosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Adenomyosis Drugs Breakdown Data by Manufacturer
3.1 Global Adenomyosis Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Adenomyosis Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Adenomyosis Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Adenomyosis Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Adenomyosis Drugs Manufacturer Market Share in 2021
3.5 Global Adenomyosis Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Adenomyosis Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Adenomyosis Drugs Market Size by Region
4.1.1 Global Adenomyosis Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Adenomyosis Drugs Revenue by Region (2017-2028)
4.2 North America Adenomyosis Drugs Revenue (2017-2028)
4.3 Europe Adenomyosis Drugs Revenue (2017-2028)
4.4 Asia-Pacific Adenomyosis Drugs Revenue (2017-2028)
4.5 South America Adenomyosis Drugs Revenue (2017-2028)
4.6 Middle East and Africa Adenomyosis Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Adenomyosis Drugs Sales in Volume by Type (2017-2028)
5.2 Global Adenomyosis Drugs Revenue by Type (2017-2028)
5.3 Global Adenomyosis Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Adenomyosis Drugs Sales in Volume by Application (2017-2028)
6.2 Global Adenomyosis Drugs Revenue by Application (2017-2028)
6.3 Global Adenomyosis Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Adenomyosis Drugs Sales by Type (2017-2028)
7.2 North America Adenomyosis Drugs Sales by Application (2017-2028)
7.3 North America Adenomyosis Drugs Market Size by Country
7.3.1 North America Adenomyosis Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Adenomyosis Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Adenomyosis Drugs Sales by Type (2017-2028)
8.2 Europe Adenomyosis Drugs Sales by Application (2017-2028)
8.3 Europe Adenomyosis Drugs Market Size by Country
8.3.1 Europe Adenomyosis Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Adenomyosis Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Adenomyosis Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Adenomyosis Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Adenomyosis Drugs Market Size by Region
9.3.1 Asia-Pacific Adenomyosis Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Adenomyosis Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Adenomyosis Drugs Sales by Type (2017-2028)
10.2 South America Adenomyosis Drugs Sales by Application (2017-2028)
10.3 South America Adenomyosis Drugs Market Size by Country
10.3.1 South America Adenomyosis Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Adenomyosis Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Adenomyosis Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Adenomyosis Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Adenomyosis Drugs Market Size by Country
11.3.1 Middle East & Africa Adenomyosis Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Adenomyosis Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Adenomyosis Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Adenomyosis Drugs
12.3 Adenomyosis Drugs Production Process
12.4 Adenomyosis Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Adenomyosis Drugs Typical Distributors
13.3 Adenomyosis Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 腺筋症治療薬の世界市場2022：ホルモン剤、抗炎症剤、その他(Global Adenomyosis Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 抗凝血薬のグローバル市場展望 2023年-2029年：ホルモン剤、抗生物質、ACE阻害剤、その他
  • 腺筋症治療薬の世界市場2022：ホルモン剤、抗炎症剤、その他
  • 腺筋症治療薬の世界市場2022：ホルモン剤、抗炎症剤、その他
  • オシメルチニブ医薬品の世界市場2022：40mg、80mg
  • クローン病治療薬の世界市場2022：抗炎症剤、免疫抑制剤、抗生物質、その他